| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 100mg | |||
| 250mg | |||
| Other Sizes |
| Targets |
β,β-Dimethylacrylshikonin targets multiple pathways. It inhibits the nuclear factor κB (NF-κB) and mitogen-activated protein kinase (MAPK) signaling pathways. It induces the expression of eNOS, VEGF, and HIF-1α through the PI3K pathway. It also inhibits ATR and ATM.
|
|---|---|
| ln Vitro |
In cell-free systems, β,β-Dimethylacrylshikonin's activity is assessed by its ability to inhibit the activation of ATR and ATM. These are key regulators of the DNA damage response. Its effect on these kinases can be measured using in vitro kinase assays. In vitro, β,β-Dimethylacrylshikonin inhibits the progression of gastric cancer cells. It induces apoptosis, inhibits angiogenesis, and suppresses pro-inflammatory mediators. It induces the expression of eNOS, VEGF, and HIF-1α through the PI3K pathway, promoting angiogenesis.
|
| ln Vivo |
In vivo, injection of β,β-Dimethylacrylshikonin combined with IR treatment significantly suppressed tumor growth in an HCT-116 xenograft model. This demonstrates its potential as a radiosensitizer and anticancer agent.
|
| Enzyme Assay |
In vitro kinase assays are used to measure the inhibition of ATR and ATM. The kinases are incubated with a substrate and ATP in the presence of the compound. The phosphorylation of the substrate is measured to determine the IC50.
|
| Cell Assay |
Cells are treated with β,β-Dimethylacrylshikonin, and its effects on signaling pathways are assessed. The phosphorylation of NF-κB and MAPK components is measured by Western blot. Apoptosis is assessed by flow cytometry. Angiogenesis is evaluated using tube formation assays.
|
| Animal Protocol |
In vivo efficacy is evaluated using xenograft mouse models. Mice bearing tumors are treated with the compound, alone or in combination with radiation. Tumor growth is monitored, and tissue samples are collected for histological and molecular analysis.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of β,β-Dimethylacrylshikonin are not well-documented. As a naphthoquinone, its oral bioavailability may be limited. Its metabolism and excretion are not well-characterized. Further studies are needed.
|
| Toxicity/Toxicokinetics |
Toxicological data for β,β-Dimethylacrylshikonin is limited. Its anticancer activity suggests it may have cytotoxic effects on cancer cells. Its safety profile requires further investigation, especially if it is to be developed as a therapeutic agent.
|
| References | |
| Additional Infomation |
β,β-Dimethacrylshikonin is a hydroxy-1,4-naphthoquinone. It has been reported in Onosma paniculata, Arnebia euchroma, and other organisms with relevant data. See also: β,β-Dimethacrylshikonin (note moved to).
β,β-Dimethylacrylshikonin is a research compound with potential anticancer and anti-inflammatory activities. It is a valuable tool for studying the NF-κB and PI3K pathways. It is not an approved drug and is for research use only. |
| Molecular Formula |
C21H22O6
|
|---|---|
| Molecular Weight |
370.3958
|
| Exact Mass |
370.141
|
| CAS # |
24502-79-2
|
| Related CAS # |
β,β-Dimethylacrylalkannin;34539-65-6
|
| PubChem CID |
479499
|
| Appearance |
Brown to reddish brown solid powder
|
| Density |
1.3±0.1 g/cm3
|
| Boiling Point |
653.2±55.0 °C at 760 mmHg
|
| Melting Point |
103ºC
|
| Flash Point |
362.8±28.0 °C
|
| Vapour Pressure |
0.0±2.1 mmHg at 25°C
|
| Index of Refraction |
1.616
|
| LogP |
4.45
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
6
|
| Rotatable Bond Count |
6
|
| Heavy Atom Count |
27
|
| Complexity |
706
|
| Defined Atom Stereocenter Count |
1
|
| SMILES |
CC(=CC[C@H](C1=CC(=O)C2=C(C=CC(=C2C1=O)O)O)OC(=O)C=C(C)C)C
|
| InChi Key |
BATBOVZTQBLKIL-QGZVFWFLSA-N
|
| InChi Code |
InChI=1S/C21H22O6/c1-11(2)5-8-17(27-18(25)9-12(3)4)13-10-16(24)19-14(22)6-7-15(23)20(19)21(13)26/h5-7,9-10,17,22-23H,8H2,1-4H3/t17-/m1/s1
|
| Chemical Name |
[(1R)-1-(5,8-dihydroxy-1,4-dioxonaphthalen-2-yl)-4-methylpent-3-enyl] 3-methylbut-2-enoate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~12.5 mg/mL (~33.75 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.08 mg/mL (5.62 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.6998 mL | 13.4989 mL | 26.9978 mL | |
| 5 mM | 0.5400 mL | 2.6998 mL | 5.3996 mL | |
| 10 mM | 0.2700 mL | 1.3499 mL | 2.6998 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
